STEPHEN A UDEM
Medical Practice in New York, NY
License number
New Jersey 25MA05311200
Issued Date
Dec 5, 1989
Expiration Date
Jun 30, 2001
Category
Medical Examiners
Type
Medical Doctor
Address
Address
New York, NY
Personal information
See more information about STEPHEN A UDEM at radaris.comName
Address
Phone
155 W 70Th St APT 6F, New York, NY 10023
155 70Th St, New York, NY 10023
155 70Th St, New York, NY 10023
Professional information
Independent Biotechnology Professional
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
Wyeth
1994 - 2006
-
VP of Vaccine Discovery Research
Wyeth Vaccines
1994 - 2006
-
Vice President Vaccine Discovery Research
Novel Methods For Rescue Of Rna Viruses
US Patent:
2003012, Jul 10, 2003
Filed:
Oct 1, 2002
Appl. No.:
10/261961
Inventors:
Christopher Parks - Boonton NJ, US
Mohinderjit Sidhu - Scotch Plains NJ, US
Stephen Udem - New York NY, US
Gerald Kovacs - Morristown NJ, US
Mohinderjit Sidhu - Scotch Plains NJ, US
Stephen Udem - New York NY, US
Gerald Kovacs - Morristown NJ, US
Assignee:
Wyeth - Madison NJ
International Classification:
C12N007/02, C07H021/04, C12N007/00, C12N007/01, C12N015/00, C12N015/09, C12N015/63, C12N015/70, C12N015/74
US Classification:
435/239000, 435/235100, 536/023720, 435/320100
Abstract:
This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to methods of producing such viruses as attenuated and/or infectious viruses, such as Measles virus (MV) and respiratory syncytial virus (RSV). One method for producing a recombinant virus from the Order Mononegavirales comprises (a) in at least one host cell, conducting transfection of a rescue composition which comprises (i) a transcription vector comprising an isolated nucleic acid molecule which comprises polynucleotide sequence encoding a genome or antigenome of a nonsegmented, negative-sense, single stranded RNA virus of the Order Mononegavirales and (ii) at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting proteins necessary for encapsidation, transcription and replication; in a host cell under conditions sufficient to permit the co-expression of these vectors and the production of the recombinant virus; (b) heating the transfected rescue composition to an effective heat shock temperature under conditions sufficient to increase the recovery of the recombinant virus; and optionally, (c) harvesting the resulting recombinant virus.
Rescue Of Canine Distemper Virus From Cdna
US Patent:
2005008, Apr 28, 2005
Filed:
Jun 22, 2001
Appl. No.:
10/312052
Inventors:
Christopher Parks - Boonton NJ, US
Mohinderjit Sidhu - New City NY, US
Pramila Walpita - Basking Ridge NJ, US
Gerald Kovacs - Ridgewood NJ, US
Stephen Udem - New York NY, US
Mohinderjit Sidhu - New City NY, US
Pramila Walpita - Basking Ridge NJ, US
Gerald Kovacs - Ridgewood NJ, US
Stephen Udem - New York NY, US
International Classification:
C12N007/00, C12N015/86
US Classification:
435235100, 435456000
Abstract:
This invention relates to a method for recombinantly producing via rescue canine distemper virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the canine distemper virus as an attenuated and/or infectious viruses. The recombinant viruses can be prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and rearrangements, in the genome can be obtained.
Rescue Of Mumps Virus From Cdna
US Patent:
7361496, Apr 22, 2008
Filed:
Aug 2, 2000
Appl. No.:
10/048384
Inventors:
David K. Clarke - Chester NY, US
J. Erik Johnson - Verona NJ, US
Mohinderjit S. Sidhu - Scotch Plains NJ, US
Stephen A. Udem - New York NY, US
J. Erik Johnson - Verona NJ, US
Mohinderjit S. Sidhu - Scotch Plains NJ, US
Stephen A. Udem - New York NY, US
Assignee:
Wyeth - Madison NJ
International Classification:
C12N 7/00
US Classification:
4352351, 435 691, 4353201, 435239, 435455, 435456, 435471, 435476
Abstract:
This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.
Immunogenic Composition And Methods
US Patent:
2012024, Sep 27, 2012
Filed:
Apr 24, 2012
Appl. No.:
13/454884
Inventors:
John Eldridge - Somers NY, US
Zimra R. Israel - New York NY, US
Michael A. Egan - Washingtonville NY, US
Stephen A. Udem - New York NY, US
Zimra R. Israel - New York NY, US
Michael A. Egan - Washingtonville NY, US
Stephen A. Udem - New York NY, US
Assignee:
WYETH LLC - Madison NJ
International Classification:
A61K 39/21, A61P 31/14, A61P 31/18, A61P 37/04, A61K 38/19, A61K 38/20
US Classification:
424 852, 4241991, 424 851
Abstract:
A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell. The method also includes administering to the subject an effective amount of a second composition comprising a recombinant vesicular stomatitis virus (rVSV) comprising a nucleic acid sequence encoding the antigen under the control of regulatory sequences directing expression thereof in the mammalian or vertebrate cell. The rVSV is in one embodiment replication competent. Kits for use in immunizations and therapeutic treatments of disease include the components and instructions for practice of this method.
Synergistic Attenuation Of Vesicular Stomatitis Virus, Vectors Thereof And Immunogenic Compositions Thereof
US Patent:
8647638, Feb 11, 2014
Filed:
Aug 31, 2012
Appl. No.:
13/600289
Inventors:
David Kirkwood Clarke - Chester NY, US
Roger Michael Hendry - Atlanta GA, US
Stephen A. Udem - New York NY, US
Christopher Lee Parks - Boonton NJ, US
Roger Michael Hendry - Atlanta GA, US
Stephen A. Udem - New York NY, US
Christopher Lee Parks - Boonton NJ, US
Assignee:
Wyeth LLC - Madison NJ
International Classification:
A61K 39/205, A61K 39/12, C12N 7/01, C12N 15/63
US Classification:
4242241, 4241991, 4352351, 4353201
Abstract:
The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV), More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.
Sequence Analysis Of The Tetravalent Rotavirus Vaccine
US Patent:
2009024, Oct 1, 2009
Filed:
Feb 3, 2009
Appl. No.:
12/365122
Inventors:
Deborah A. Buonagurio - Rye NY, US
Alice F. Georgiu - Montgomery NY, US
Robert A. Lerch - New Hempstead NY, US
Bruce B. Mason - Downington PA, US
Shridhara C. Murthy - Ann Arbor MI, US
Ruth S. Rappaport - Strafford PA, US
Mohinder S. Sidhu - New City NY, US
Stephen A. Udem - New York NY, US
Timothy J. Zamb - Nyack NJ, US
Alice F. Georgiu - Montgomery NY, US
Robert A. Lerch - New Hempstead NY, US
Bruce B. Mason - Downington PA, US
Shridhara C. Murthy - Ann Arbor MI, US
Ruth S. Rappaport - Strafford PA, US
Mohinder S. Sidhu - New City NY, US
Stephen A. Udem - New York NY, US
Timothy J. Zamb - Nyack NJ, US
Assignee:
Services - Rockville MD
International Classification:
C12P 21/02, C12N 15/11, C12N 15/00, C12N 1/21, C12N 5/00, C12N 1/19, C12N 5/06
US Classification:
435 691, 536 2372, 4353201, 43525233, 435348, 4352542, 435358, 435365
Abstract:
Isolated nucleic acid molecules comprising a gene segment from a rhesus rotavirus (RRV) or from one of three rhesus:human reassortant viruses are disclosed, including isolated nucleic acid molecules having a sequence selected from the group consisting of: SEQ ID NO: 1-14, inclusive, and isolated nucleic acid molecules encoding a protein having a sequence selected from the group consisting of SEQ ID NO: 15-28, inclusive, as well as variants of the isolated nucleic acid molecules.
Synergistic Attenuation Of Vesicular Stomatitis Virus, Vectors Thereof And Immunogenic Compositions Thereof
US Patent:
8287878, Oct 16, 2012
Filed:
Apr 5, 2005
Appl. No.:
11/547236
Inventors:
David Kirkwood Clarke - Chester NY, US
Roger Michael Hendry - Warwick NY, US
Stephen A. Udem - New York NY, US
Christopher Lee Parks - Boonton NJ, US
Roger Michael Hendry - Warwick NY, US
Stephen A. Udem - New York NY, US
Christopher Lee Parks - Boonton NJ, US
Assignee:
Wyeth LLC - Madison NJ
International Classification:
A61K 39/12, C12N 7/01
US Classification:
4241991, 4352351, 4353201
Abstract:
The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV). More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.
Rescue Of Mumps Virus From Cdna
US Patent:
2007025, Nov 8, 2007
Filed:
Jun 27, 2007
Appl. No.:
11/823309
Inventors:
David Clarke - Chester NY, US
J. Johnson - Verona NJ, US
Mohinderjit Sidhu - Scotch Plains NJ, US
Stephen Udem - New York NY, US
J. Johnson - Verona NJ, US
Mohinderjit Sidhu - Scotch Plains NJ, US
Stephen Udem - New York NY, US
Assignee:
Wyeth - Madison NJ
International Classification:
A61K 39/165, A61K 39/295
US Classification:
424202100, 424212100
Abstract:
This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotidelpoly/nucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.
Fusogenic, Self-Propagating Blebs As Immunogenic Compositions
US Patent:
7541038, Jun 2, 2009
Filed:
Jun 2, 2004
Appl. No.:
10/559429
Inventors:
Gerald Raul Kovacs - Potomac MD, US
Xiaoyan Mo - Boxborough MA, US
Nikolaos Vasilakis - Galveston TX, US
Sangeeta Bhargava - Potomac MD, US
Timothy Joseph Zamb - Nyack NY, US
Stephen Alexander Udem - New York NY, US
Xiaoyan Mo - Boxborough MA, US
Nikolaos Vasilakis - Galveston TX, US
Sangeeta Bhargava - Potomac MD, US
Timothy Joseph Zamb - Nyack NY, US
Stephen Alexander Udem - New York NY, US
Assignee:
Wyeth Holdings Corporation - Madison NJ
International Classification:
A61K 39/155, C12N 15/86
US Classification:
4241991, 4242111, 4353201, 4352351
Abstract:
Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.